<DOC>
	<DOCNO>NCT01089023</DOCNO>
	<brief_summary>This open-label single-arm study evaluate safety , tolerability efficacy tocilizumab [ RoActemra/Actemra ] patient moderate severe rheumatoid arthritis experience inadequate clinical response stable dose non-biologic disease modify anti-rheumatic drug ( DMARD ) anti-tumor necrosis factor ( TNFs ) . RoActemra/Actemra administer monotherapy combination DMARDs . RoActemra/Actemra administer intravenous infusion dose 8 mg/kg every 4 week total 6 infusion . The anticipated time study treatment 24 week . The target sample size 50-150 patient .</brief_summary>
	<brief_title>A Study Tocilizumab Monotherapy Combination With DMARDs Patients With Moderate Severe Active Rheumatoid Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>adult patient , &gt; /=18 year age moderate severe rheumatoid arthritis ( DAS28 &gt; 3.2 ) 6 month duration inadequate clinical response nonbiologic DMARDs antiTNF bodyweight &lt; /=150 kg rheumatic autoimmune disease inflammatory joint disease RA major surgery within 8 week prior screen plan major surgery within 6 month follow screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>